Lidocaine Shortage: What Providers and Prescribers Need to Know in 2026

The lidocaine shortage has been a persistent challenge for healthcare providers since at least 2012, with the ASHP first listing it then. Yet as of early 2026, it remains an active, ongoing concern that affects procedural care across specialties — from dermatology and dentistry to emergency medicine and obstetrics.

This guide provides an up-to-date clinical summary for providers, covering shortage status, formulations most at risk, evidence-based substitution strategies, and communication approaches for your patients.

Current Shortage Status (2026)

As of early 2026, the following lidocaine products have shortage status per ASHP and the FDA:

• Pfizer lidocaine injection (all concentrations): Multiple vial sizes on back order due to manufacturing delays and increased demand. Estimated restocking for 0.5% 50 mL vials: March 2026; for 2% emergency Ansyr syringes: April 2026.
• LifeShield Abboject syringes: Discontinued mid-2025 — no longer a stocking option.
• Lidocaine viscous 2%: Listed on the FDA shortage database; relevant for palliative care, oncology, and ENT practices.
• Available alternatives: Eugia US and Sintetica have some lidocaine injection inventory available through Cardinal Health, McKesson, and Cencora — but supply is inconsistent and varies by region.

Root Causes: Why This Shortage Persists

Understanding the underlying causes is important for advocacy and long-term planning:

• Manufacturing duopoly: Only Pfizer and Fresenius Kabi USA manufacture injectable lidocaine in the US, creating a fragile single-point-of-failure supply structure.
• No domestic API production: Despite 39% of US lidocaine products being manufactured domestically, there are no FDA-registered domestic suppliers of the active pharmaceutical ingredient.
• Import restrictions: Regulatory inconsistencies make importing lidocaine from Canada (similar quality standards) more difficult than importing from China, limiting the pool of alternative suppliers during shortages.
• Low commercial incentive: Lidocaine's thin profit margins reduce pharmaceutical industry motivation to invest in additional manufacturing capacity.

Clinical Substitution Strategies by Practice Area

When lidocaine is unavailable, the appropriate substitution depends on the clinical context. The ASHP provides comparison tables for bupivacaine vs. lidocaine pharmacokinetics. Key differences: bupivacaine has a slower onset but much longer duration (4–12 hours); ropivacaine offers a better cardiac safety profile than bupivacaine.

Dermatology / Office-Based Procedures:

• Bupivacaine 0.25%–0.5% (infiltration): equivalent or superior local anesthesia, longer duration — useful when patients want extended post-procedure comfort
• AADA guidance on diluting existing lidocaine stock with normal saline (consult AADA member resources for protocol)

Dentistry:

• Mepivacaine 3% (no vasoconstrictor) or mepivacaine 2% with 1:20,000 levonordefrin: excellent rapid-onset substitute for lidocaine in most dental procedures
• Articaine 4% with epinephrine: particularly effective for inferior alveolar nerve blocks

Obstetrics:

• Ropivacaine 0.1%–0.2% for labor epidurals: lower cardiac toxicity than bupivacaine, preserves some motor function — preferred by SOAP (Society for Obstetric Anesthesia and Perinatology) during shortage periods

Emergency Medicine / Cardiac:

• IV amiodarone: first-line for ventricular arrhythmias when IV lidocaine is unavailable (lidocaine is already considered second-line)
• Mexiletine (oral): for maintenance antiarrhythmic therapy in patients previously on lidocaine infusions

Pain Management (Postherpetic Neuralgia):

• Capsaicin 8% patch (Qutenza): clinically superior to lidocaine 5% patch for PHN in head-to-head trials over 24 weeks
• Gabapentin or pregabalin: first-line oral options for PHN per IASP guidelines

Inventory and Procurement Strategies

For healthcare organizations and practice managers:

• Check with multiple distributors — Cardinal Health, McKesson, and Cencora may have different inventory from different manufacturers (Eugia US, Sintetica)
• Avoid distributor price gouging — the AADA has published guidance on this for member physicians
• Monitor the ASHP Drug Shortage Resource Center and FDA Drug Shortages Database weekly for updates
• Implement formulary-level substitution protocols to ensure standardized responses when lidocaine stock runs low

Communicating With Patients About the Shortage

For patients filling outpatient prescriptions (lidocaine patches, viscous), providers can recommend medfinder — a paid service that contacts pharmacies in a patient's area to find current stock and texts them the results. This reduces the burden of pharmacy searching on both patient and staff.

medfinder for Providers

medfinder works with providers to help their patients locate hard-to-find medications at nearby pharmacies. Visit medfinder.com/providers to learn more, or see our guide on how to help your patients find lidocaine in stock.